





Polymeric Nanocarriers for the Delivery of Ionizable Therapeutics: Formulation, Internal Structure, and Large-Scale Process Development


Kurt Ristroph

Advisor: Prof. Bob Prud'homme


Scalable nanocarrier formulation platform: Flash NanoPrecipitation (FNP)



Key challenges for FNP: “intermediate” hydrophobicity & block copolymer cost




“Bulk nanoprecipitation” poor mixing:



Adapting FNP for use with low-cost stabilizers and continuous drying


Flash NanoPrecipitation (FNP)

Hydrophobic molecule encapsulation




Low-cost stabilizer

Amphiphilic modified cellulosic



Dissolution kinetics in intestinal fluid




Ristrop et al., *J. Trans. Med.* 2019

Adapting FNP to encapsulate hydrophilic biologics


Flash NanoPrecipitation (FNP)

Hydrophobic molecule encapsulation




Hydrophobic ion pairing (HIP)



Solubility engineering for hydrophilic APIs



- Forms ~100nm NCs, tunable
- 90-100% EE
- 30-40% API loading
- *Release rate varies with counterion chemistry and quantity; why?*





Liquid crystalline structures in NC cores control release rate (poster 300)




- Phase behavior can be controlled with choice and quantity of counterion.
- Allows straightforward method of tuning release rate.

Ristroph et al., JCIS 2020
Ristroph et al., Mol. Pharm 2021

Nanocarrier targeting: macrophage-targeted antitubercular NCs (poster 301)




PCL-*b*-PEG-HM



*hexamannose
targeting moiety for
macrophages*

ecuminic core




In press, Adv. Mat. Tech.


In vivo efficacy of NCs made by FNP with HIP

Ovalbumin (OVA): 43 kDa, pI = 5.2

- EE: 88% OVA loading: 29%
- NC formulation improved immunogenicity *in vivo* in a nasal vaccine mouse model



Efficacy of pulmonary delivered polymyxin B nanoparticles against *Ab* N16870.213 in mouse lung infection



Markwalter et al., *JCR* 2021

Acknowledgements and conclusions

PRINCETON
School of Engineering and Applied Science

moderna

Bristol Myers Squibb™

Lilly
Genentech

WuXi AppTec

optimeos
life sciences inc.

Australian
Synchrotron

BILL & MELINDA
GATES foundation

MMV
Medicines for Malaria Venture

KELLER CENTER
NSF
GRFP
NSF GRADUATE RESEARCH FELLOWSHIP PROGRAM

- We are continuing to expand the Flash NanoPrecipitation platform to enable novel nanoformulations for enhanced delivery.
- This work will continue in the newly-formed Ristroph Lab at the Purdue University Department of Agricultural & Biological Engineering.
www.ristrophlab.com

SCHMIDT
SCIENCE FELLOWS

PURDUE
UNIVERSITY®
AGRICULTURAL & BIOLOGICAL ENGINEERING

